Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2014 | (b) 2015 | (c) 2016 | (d) 2017 | (e) 2018 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | 77,337,857 | 105,234,559 | 55,634,984 | 51,441,732 | 63,291,987 | 352,941,119 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf.... | 0 | |||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | 0 | |||||
| 4 | Total. Add lines 1 through 3 | 77,337,857 | 105,234,559 | 55,634,984 | 51,441,732 | 63,291,987 | 352,941,119 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f).. | 42,585,598 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 310,355,521 | |||||
Calendar year
(or fiscal year beginning in) ![]() |
(a) 2014 | (b) 2015 | (c) 2016 | (d) 2017 | (e) 2018 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 77,337,857 | 105,234,559 | 55,634,984 | 51,441,732 | 63,291,987 | 352,941,119 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 3,542,123 | 2,523,145 | 2,265,964 | 5,667,273 | 5,221,701 | 19,220,206 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | 153,632 | 336,857 | 51,821 | 124,523 | 34,200 | 701,033 |
| 11 | Total support. Add lines 7 through 10 | 372,862,358 | |||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2014 | (b) 2015 | (c) 2016 | (d) 2017 | (e) 2018 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2014 | (b) 2015 | (c) 2016 | (d) 2017 | (e) 2018 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 1-1/2% of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by .035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | ||
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
||
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | ||
| 4 Amounts paid to acquire exempt-use assets | ||
| 5 Qualified set-aside amounts (prior IRS approval required) | ||
| 6 Other distributions (describe in Part VI). See instructions | ||
| 7Total annual distributions. Add lines 1 through 6. | ||
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
||
| 9 Distributable amount for 2018 from Section C, line 6 | ||
| 10 Line 8 amount divided by Line 9 amount | ||
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2018 |
(iii) Distributable Amount for 2018 |
|
|---|---|---|---|---|
|
1
Distributable amount for 2018 from Section C, line 6 |
||||
|
2
Underdistributions, if any, for years prior to 2018 (reasonable cause required-- explain in Part VI). See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2018: | ||||
| a From 2013....... | ||||
| b From 2014....... | ||||
| c From 2015....... | ||||
| d From 2016....... | ||||
| e From 2017....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2018 distributable amount | ||||
|
i
Carryover from 2013 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from 3f. | ||||
| 4Distributions for 2018 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2018 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from 4. | ||||
|
5
Remaining underdistributions for years prior to 2018, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2018. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2019. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2014...... | ||||
| b Excess from 2015..... | ||||
| c Excess from 2016..... | ||||
| d Excess from 2017..... | ||||
| e Excess from 2018..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.
Go to www.irs.gov/Form990 for the latest information.
| Return Reference | Explanation |
|---|---|
| FORM 990, PART I, QUESTION 6 - VOLUNTEERS | VOLUNTEERS SERVE IN A VARIETY OF WAYS, BUT THE GREATEST NUMBERS OF VOLUNTEERS ASSIST WITH THE SUSAN G. KOMEN 3 DAY SERIES. |
| FORM 990, PART III - PROGRAM SERVICE ACCOMPLISHMENTS | SUSAN G. KOMEN IS A LEADING GLOBAL BREAST CANCER ORGANIZATION, HAVING FUNDED MORE BREAST CANCER RESEARCH THAN ANY OTHER NONPROFIT OUTSIDE THE U.S. GOVERNMENT WHILE PROVIDING REAL TIME HELP TO THOSE FACING THE DISEASE. SINCE ITS FOUNDING IN 1982, KOMEN HAS FUNDED MORE THAN $1 BILLION IN BREAST CANCER RESEARCH AND PROVIDED OVER $2.3 BILLION IN FUNDING FOR PATIENT NAVIGATION, SCREENING, DIAGNOSIS, TREATMENT, EDUCATION, HEALTH SYSTEMS IMPROVEMENT, AND PSYCHOSOCIAL SUPPORT PROGRAMS SERVING MILLIONS OF PEOPLE IN MORE THAN 60 COUNTRIES WORLDWIDE. KOMEN WAS FOUNDED BY NANCY G. BRINKER, WHO PROMISED HER SISTER, SUSAN G. KOMEN, THAT SHE WOULD END THE DISEASE THAT CLAIMED SUZY'S LIFE. RESEARCH SINCE ITS FOUNDING IN 1982, KOMEN'S RESEARCH INVESTMENTS HAVE CONTRIBUTED TO MANY MAJOR ADVANCES IN BREAST CANCER SCIENCE. THE PROGRESS HAS BEEN SIGNIFICANT - TODAY, WE KNOW THAT BREAST CANCER IS MORE THAN A SINGLE DISEASE. WE HAVE A BETTER UNDERSTANDING OF THE GENETICS OF BREAST CANCER AND THE CRITICAL NEED TO TAILOR SCREENING, DIAGNOSIS, TREATMENT, AND PREVENTION STRATEGIES TO INDIVIDUALS THROUGH ADVANCES IN PRECISION MEDICINE. KOMEN'S RESEARCH PROGRAMS ARE FOCUSED ON BREAKTHROUGH RESEARCH TO PREVENT AND CURE BREAST CANCER THROUGH BETTER APPROACHES FOR EARLY DETECTION AND DIAGNOSIS, UNDERSTANDING METASTASIS AND RECURRENCE, AND DEVELOPING NOVEL THERAPIES FOR ALL STAGES OF BREAST CANCER, WITH THE GOAL OF SUPPORTING WORK THAT HAS SIGNIFICANT POTENTIAL TO LEAD TO NEW TREATMENTS AND TECHNOLOGIES THAT WILL REDUCE THE NUMBER OF BREAST CANCER DEATHS IN THE U.S. BY 50 PERCENT BY 2026. KOMEN'S RESEARCH PROGRAMS ARE GUIDED BY 67 OF THE WORLD'S LEADERS IN BREAST CANCER RESEARCH, ONCOLOGY AND ADVOCACY. THE SCIENTIFIC ADVISORY BOARD ASSISTS KOMEN IN SETTING ITS RESEARCH STRATEGY AND PRIORITIZING ITS RESEARCH INVESTMENT. THE KOMEN SCHOLARS LEAD AND PARTICIPATE IN KOMEN'S WORLD-CLASS SCIENTIFIC PEER REVIEW PROCESS. OUR ADVOCATES IN SCIENCE BRING THE COLLECTIVE PATIENT VOICE TO KOMEN'S RESEARCH PROGRAMS AND SCIENTIFIC ACTIVITIES, EMPHASIZING URGENCY AND PATIENT IMPACT. KOMEN AWARDS GRANTS TO INDIVIDUAL SCIENTISTS, RESEARCH TEAMS, AND ORGANIZATIONS AROUND THE WORLD THROUGH A FAIR, TRANSPARENT, RIGOROUS, AND COMPETITIVE REVIEW PROCESS THAT ENSURES MAXIMUM IMPACT FOR OUR RESEARCH INVESTMENT. IN FY19, KOMEN AWARDED 60 GRANTS THROUGH ITS RESEARCH PROGRAMS TO SUPPORT SCIENTIFIC RESEARCH, COLLABORATIONS AND TRAINING IN THE UNITED STATES AND OTHER COUNTRIES, INCLUDING: AUSTRALIA, CANADA, FRANCE, ITALY, AND SOUTH AFRICA. WE HAVE A STRONG COMMITMENT TO SUPPORTING THE NEXT GENERATION OF LEADERS IN BREAST CANCER RESEARCH. SUSTAINING THE WORKFORCE IS CRITICAL; WE WANT TO UNLEASH THEIR CREATIVITY AND INNOVATION TO DRIVE DISCOVERY. THE PUBLIC CANNOT AFFORD TO LOSE PROMISING EARLY CAREER INVESTIGATORS DUE TO A LACK OF FUNDING OPPORTUNITIES. TO THAT END, KOMEN AWARDED CAREER CATALYST RESEARCH GRANTS TO SUPPORT EARLY CAREER INVESTIGATORS IN BREAST CANCER RESEARCH IN THEIR EFFORTS TO CONQUER METASTASIS. KOMEN ALSO AWARDED GRADUATE TRAINING IN DISPARITIES RESEARCH COMPETITIVE RENEWAL GRANTS TO SUPPORT TRAINING LEADERS IN THE FIELD OF BREAST CANCER DISPARITIES RESEARCH. KOMEN ALSO OFFERED LEADERSHIP GRANTS TO SUPPORT KEY WORK BY LEADERS IN THE FIELD OF BREAST CANCER RESEARCH. EACH MECHANISM IS DESCRIBED BELOW. CAREER CATALYST RESEARCH GRANTS (CCR): CCR GRANTS PROVIDE UNIQUE OPPORTUNITIES FOR SCIENTISTS WHO HAVE HELD FACULTY POSITIONS FOR NO MORE THAN 5 YEARS AT THE TIME OF APPLICATION TO ACHIEVE RESEARCH INDEPENDENCE. THE GOAL OF THE FY19 CCR GRANTS IS TO SUPPORT OUTSTANDING TRANSLATIONAL RESEARCH FOCUSED ON THE UNDERSTANDING, DETECTION, AND TREATMENT OF METASTATIC BREAST CANCER WHICH WILL LEAD TO A REDUCTION IN BREAST CANCER DEATHS BY 2026. GRADUATE TRAINING IN DISPARITIES RESEARCH - COMPETITIVE RENEWAL GRANTS (GTDR-CR): GTDR-CR GRANTS PROVIDES FUNDING TO OUTSTANDING PROGRAMS TO ESTABLISH AND/OR SUSTAIN INNOVATIVE TRAINING PROGRAMS FOR GRADUATE STUDENTS SEEKING CAREERS DEDICATED TO ACHIEVING HEALTH EQUITY. THE GOAL OF THE FY19 COMPETITIVE RENEWAL IS TO SUPPORT PROGRAMS FOR AN ADDITIONAL YEAR TO MAINTAIN SUCCESSFUL PROGRAMS THAT ARE WORKING TOWARDS ACHIEVING KOMEN'S BOLD GOAL. LEADERSHIP GRANTS: LEADERSHIP GRANTS PROVIDE SUPPORT FOR HYPOTHESIS-DRIVEN RESEARCH PROJECTS CONDUCTED BY THE DISTINGUISHED BREAST CANCER RESEARCHERS AND CLINICIANS WHO SERVE AS KOMEN'S SCIENTIFIC ADVISORS AND SEEK TO DISCOVER AND DELIVER THE CURES FOR BREAST CANCER. OPPORTUNITY GRANTS / STRATEGIC PARTNERSHIP AND PROGRAM GRANTS (OG/SPP): OG AND SPP GRANTS SUPPORT SPECIAL RESEARCH PROJECTS, PROGRAMS, AND COLLABORATIONS THAT LEVERAGE RESEARCH AND COMMUNITY RESOURCES TO FACILITATE THE DEVELOPMENT OF THE INFRASTRUCTURE, TOOLS, AND OTHER MEANS TO ACCELERATE THE TRANSLATION OF SCIENTIFIC DISCOVERIES FROM BENCH TO BEDSIDE TO CURBSIDE. FUNDING FROM ORGANIZATIONS LIKE KOMEN AND ITS SUPPORTERS HAS PROVEN CRITICAL FOR ALL THESE ACTIVITIES, PARTICULARLY FOR CANCER RESEARCH AND FOR CLINICAL TRIALS. KOMEN'S RESEARCH INVESTMENT THROUGH THESE GRANT MECHANISMS SUPPORTS PROJECTS THAT AIM TO, AMONG OTHER THINGS: (A) DEVELOP NOVEL TREATMENT STRATEGIES FOR METASTATIC DISEASE; (B) CREATE NEW STRATEGIES TO DETECT AND PREVENT RECURRENCE; (C) OVERCOME TREATMENT RESISTANCE; (D) UNDERSTAND AND ADDRESS DISPARITIES IN OUTCOMES; (E) ACCELERATE MEDICAL DISCOVERY AND DELIVERY USING DATA SCIENCE; AND (F) BUILDING ESSENTIAL TOOLS AND RESOURCES TO DRIVE SCIENTIFIC DISCOVERY. EXAMPLES OF RESEARCH GRANTS AWARDED IN FY19 INCLUDE: (A) DEVELOP NOVEL TREATMENT STRATEGIES FOR METASTATIC BREAST CANCER: JOE GRAY, PH.D., OF OREGON HEALTH & SCIENCE UNIVERSITY, WAS AWARDED A LEADERSHIP GRANT TO IMPROVE THE TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER. HE WILL IDENTIFY FDA-APPROVED DRUGS THAT COULD INCREASE THE EFFICACY OF IMMUNE THERAPIES AND THEN TEST THOSE DRUGS IN PRECLINICAL MODELS. THE GOAL OF THIS STUDY IS TO BETTER INFORM THERAPEUTIC STRATEGIES FOR THESE PATIENTS BY ENHANCING THE IMMUNE SYSTEM'S ABILITY TO KILL THE CANCER CELLS. |
| (B) CREATE NEW STRATEGIES TO DETECT AND PREVENT RECURRENCE | ERIC WINER, M.D., OF DANA-FARBER CANCER INSTITUTE, WAS AWARDED A LEADERSHIP GRANT TO IDENTIFY NEW RISK FACTORS OF LATE RECURRENCE OF ESTROGEN RECEPTOR-POSITIVE (ER+) BREAST CANCER. DR. WINER WILL EXAMINE THE IMPACT OF RISK FACTORS SUCH AS BMI, POST-DIAGNOSIS WEIGHT GAIN, POST-DIAGNOSIS PHYSICAL ACTIVITY, AND DIET ON LATE RECURRENCE AND IDENTIFY POTENTIAL THERAPEUTIC INTERVENTIONS. (C) OVERCOME TREATMENT RESISTANCE: AKI MORIKAWA, M.D., PH.D, OF UNIVERSITY OF MICHIGAN, WAS AWARDED A CAREER CATALYST RESEARCH GRANT TO STUDY WAYS TO IMPROVE TREATMENT RESPONSE FOR BREAST CANCER PATIENTS THAT HAVE DEVELOPED BRAIN METASTASES. DR. MORIKAWA WILL TEST THE EFFECTIVENESS OF A LARGE PANEL OF DRUGS ON BRAIN METASTASES SAMPLES FROM PATIENTS. THE GOAL IS TO DETERMINE IF REAL-TIME DRUG TESTING CAN GUIDE TREATMENT DECISIONS IN THE CLINIC AND IMPROVE OUTCOMES FOR BREAST CANCER PATIENTS WHO DEVELOP BRAIN METASTASES. (D) UNDERSTAND AND ADDRESS DISPARITIES IN OUTCOMES: LAUREN MCCULLOUGH, PH.D., OF EMORY UNIVERSITY, WAS AWARDED A CAREER CATALYST RESEARCH GRANT TO IDENTIFY CONTRIBUTORS TO POOR OUTCOMES IN A LARGE DIVERSE POPULATION IN GEORGIA, INCLUDING SOCIOECONOMIC FACTORS, URBAN/RURAL BARRIERS AND RACIAL/ETHNIC FACTORS WHICH CAN ALL LEAD TO DIFFERENCES IN BREAST CANCER METASTASIS OUTCOMES. HER TEAM WILL WORK TO UNDERSTAND WHY THESE DISPARITIES EXIST AND INFORM FUTURE THERAPEUTIC, BEHAVIORAL AND POLICY INTERVENTIONS TO IMPROVE OUTCOMES IN MARGINALIZED POPULATIONS. MELINA ARNOLD, PH.D., OF THE INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, WAS AWARDED A CAREER CATALYST RESEARCH GRANT TO CONDUCT THE FIRST INTERNATIONAL STUDY TO DETERMINE THE TRUE BURDEN OF METASTATIC BREAST CANCER AMONG HIGH-INCOME COUNTRIES. USING POPULATION-BASED DATA AND CANCER REGISTRIES, DR. ARNOLD WILL DETERMINE IF THERE ARE DIFFERENCES IN SURVIVAL OF WOMEN WITH METASTATIC BREAST CANCER ACROSS COUNTRIES AND IDENTIFY FACTORS THAT CONTRIBUTE TO DIFFERENCES IN OUTCOMES. THIS INFORMATION WILL BE USED TO CREATE RECOMMENDATIONS TO HELP ADDRESS METASTATIC BREAST CANCER DISPARITIES AND IMPROVE OUTCOMES. (E) ACCELERATE MEDICAL DISCOVERY AND DELIVERY USING DATA SCIENCE: REGINA BARZILAY, PH.D., OF THE MASSACHUSETTS INSTITUTE OF TECHNOLOGY, WAS AWARDED A LEADERSHIP GRANT TO DEVELOP AN ACCURATE RISK ASSESSMENT MODEL TO PREDICT PATIENTS AT HIGH RISK OF DEVELOPING PRIMARY BREAST CANCER. DR. BARZILAY WILL USE A LARGE COLLECTION OF PATIENTS' MAMMOGRAPH IMAGES WITH KNOWN OUTCOMES TO TEACH MACHINES (ARTIFICIAL INTELLIGENCE) TO IDENTIFY FEATURES THAT PREDICT BREAST CANCER RISK. OVERALL, THE GOAL OF THIS PROJECT IS TO IMPROVE EARLY DETECTION OF BREAST CANCER BY IDENTIFYING WOMEN AT HIGH RISK WHO MIGHT BENEFIT FROM A MORE PERSONALIZED BREAST CANCER SCREENING PROGRAM. MIA LEVY, M.D., OF RUSH UNIVERSITY MEDICAL CENTER WAS AWARDED A LEADERSHIP GRANT TO DEVELOP NOVEL DOCUMENTATION AND REPORTING STRATEGIES WITHIN THE PATIENT ELECTRONIC HEALTH RECORD THAT WOULD ALLOW FOR COLLECTION AND REPORTING OF OUTCOMES RELATED TO THE MANAGEMENT OF ADJUVANT ENDOCRINE THERAPY (AET), DEFINED AS LEARNING HEALTHCARE SYSTEM (LHS). THE ULTIMATE GOAL OF THIS STUDY IS TO IMPLEMENT THE LHS AND CHANGE HEALTHCARE DELIVERY FOR PATIENTS WITH BREAST CANCER, DECREASING RATES OF RECURRENCE AND DEATH FROM BREAST CANCER. (F) BUILDING ESSENTIAL TOOLS AND RESOURCES TO DRIVE SCIENTIFIC DISCOVERY JOHNS HOPKINS UNIVERSITY WAS AWARDED A SPONSORED PROGRAMS GRANT TO SUPPORT THE TRANSLATIONAL BREAST CANCER RESEARCH CONSORTIUM (TBCRC). THE TBCRC IS A COLLABORATION OF 19 CLINICAL SITES THAT WORK TOGETHER TO CONDUCT INNOVATIVE, HIGH-IMPACT, BIOLOGICALLY-DRIVEN TRANSLATIONAL AND CLINICAL RESEARCH TO IMPROVE OUTCOMES FOR BREAST CANCER PATIENTS. SINCE 2006, THE TBCRC HAS DEVELOPED 50 CLINICAL TRIALS, ABOUT HALF OF WHICH HAVE FOCUSED ON METASTATIC BREAST CANCER, DRUG RESISTANCE AND/OR RECURRENCE. TBCRC FINDINGS HAVE BEEN REPORTED IN OVER 80 SCIENTIFIC PEER REVIEWED PUBLICATIONS AND PRESENTATIONS TO DATE, INCLUDING 8 JOURNAL ARTICLES, AND 10 POSTER PRESENTATIONS, 3 POSTER DISCUSSIONS AND 1 TALK AT SCIENTIFIC CONFERENCES IN FY19. THE SUSAN G. KOMEN TISSUE BANK AT THE INDIANA UNIVERSITY SIMON CANCER CENTER (KTB), WAS AWARDED A SPONSORED PROGRAMS GRANT TO SUPPORT THE WORLD'S ONLY BIOREPOSITORY OF HEALTHY BREAST TISSUE. THE KTB COLLECTS AND STORES HEALTHY TISSUE AND BLOOD SAMPLES FROM DIVERSE POPULATIONS OF WOMEN REPRESENTING THE ENTIRE CONTINUUM OF BREAST DEVELOPMENT FROM PUBERTY TO MENOPAUSE. THE SAMPLES CAN BE UTILIZED BY RESEARCHERS WORLDWIDE TO STUDY BREAST ONCOGENESIS (WHEN CANCER FORMS AND NORMAL CELLS ARE TRANSFORMED INTO CANCER CELLS). SINCE ITS FOUNDING IN 2007, THE KTB HAS COLLECTED BREAST TISSUE SPECIMENS FROM MORE THAN 5,000 HEALTHY DONORS AND BLOOD FROM OVER 11,000 INDIVIDUALS. TO DATE, KTB'S RESOURCES HAVE LED TO 44 SCIENTIFIC PEER REVIEWED PUBLICATIONS, INCLUDING 5 JOURNAL ARTICLES IN FY19. EDUCATION AND PATIENT SUPPORT: KOMEN IS A TRUSTED SOURCE OF BREAST CANCER INFORMATION FOR PEOPLE ALL OVER THE WORLD AND IS INSTRUMENTAL IN CONNECTING PEOPLE WITH THE RESOURCES THEY NEED IN THEIR FIGHT AGAINST BREAST CANCER. OUR WEBSITE, KOMEN.ORG, PROVIDES CURRENT, SAFE, ACCURATE, COMPREHENSIVE, AND UNBIASED INFORMATION ABOUT BREAST CANCER, BASED ON SCIENTIFIC EVIDENCE. CONTENT IS OFFERED IN A VARIETY OF FORMATS INCLUDING INTERACTIVE VIDEO USING ANIMATION AND VOICEOVER IN ENGLISH AND SPANISH, ILLUSTRATIONS, CHARTS, GRAPHS, AND SHORT VIDEOS TO MEET THE LEARNING PREFERENCES AND NEEDS OF OUR WEB VISITORS. THE "ABOUT BREAST CANCER" SECTION OF KOMEN'S WEBSITE, CO-DEVELOPED WITH HARVARD MEDICAL SCHOOL FACULTY AND DANA-FARBER/BRIGHAM AND WOMEN'S CANCER CENTER STAFF, RECEIVED MORE THAN 5.5 MILLION PAGE VIEWS DURING FY19. KOMEN ALSO PROVIDES EVIDENCE-BASED, EASY-TO-READ EDUCATIONAL MATERIALS IN DOWNLOADABLE FORMATS ON KOMEN.ORG. EXAMPLES OF KOMEN EDUCATIONAL MATERIALS INCLUDE: A) BREAST SELF-AWARENESS MESSAGE CARDS IN MORE THAN 40 LANGUAGES, B) BREAST CANCER SPECIFIC BROCHURES AND FACTSHEETS, C) BOOKLETS WITH SUPPORT INFORMATION FOR SURVIVORS AND CO-SURVIVORS, AND D) TOOLKITS FOR BREAST CANCER OUTREACH AND EDUCATION FOR HISPANIC/LATINO IN ENGLISH AND SPANISH AND FOR BLACK AND AFRICAN-AMERICAN COMMUNITIES. THE SUSAN G. KOMEN "1-877 GO KOMEN" (1-877-465-6636) BREAST CARE HELPLINE OFFERS BREAST CANCER EDUCATION, PSYCHOSOCIAL SUPPORT, AND INFORMATION ABOUT COMMUNITY RESOURCES FOR PATIENTS, FAMILIES, AND FRIENDS. THE CLINICAL TRIAL INFORMATION HELPLINE PROVIDES INFORMATION, RESOURCES, COACHING AND SUPPORT RELATED TO BREAST CANCER CLINICAL TRIALS. THE HELPLINE OPERATES FROM 9 A.M. - 10 P.M. E.T. THE SERVICE IS OFFERED IN ENGLISH, SPANISH, AND TAGALOG. DURING FY19, THE KOMEN HELPLINE RESPONDED TO MORE THAN 15,000 CALLS AND EMAILS. IN ADDITION, IN FY19 KOMEN PARTNERED WITH LIVING BEYOND BREAST CANCER TO DEVELOP AND DELIVER A CONFERENCE FOR WOMEN LIVING WITH METASTATIC BREAST CANCER IN THE WASHINGTON, D.C. REGION. THE CONFERENCE BRINGS PEOPLE WITH METASTATIC BREAST CANCER, CAREGIVERS, HEALTHCARE PROFESSIONALS, HEALTHCARE ORGANIZATIONS, SUPPORT ORGANIZATIONS AND OTHERS, WHO PARTICIPATE IN THE CARE OF PATIENTS WITH METASTATIC BREAST CANCER, TO DISCUSS SCIENTIFIC BREAKTHROUGHS, ONGOING CLINICAL TRIALS, QUALITY OF LIFE, AND INTEGRATIVE MEDICINE. THE CONFERENCE IS DESIGNED TO FILL THE NEEDS OF THE METASTATIC BREAST CANCER COMMUNITY AND SEEKS TO STRENGTHEN METASTATIC BREAST CANCER VOICES IN THE NATIONAL CAPITAL REGION BY CREATING OPPORTUNITIES FOR LEARNING, ENGAGEMENT AND ACTION. BREAST CANCER IS THE MOST COMMON CANCER IN WOMEN, WORLDWIDE, AND THE NUMBER OF CASES IS INCREASING IN NEARLY EVERY COUNTRY. THE NUMBER OF NEW BREAST CANCER CASES HAS MORE THAN DOUBLED AROUND THE WORLD IN THE LAST THREE DECADES, WITH HIGHEST INCREASES OBSERVED IN LOW- AND MIDDLE-INCOME COUNTRIES. THESE TRENDS ARE CONCERNING, WHICH IS WHY KOMEN WORKS TIRELESSLY TO PROVIDE SUPPORT TO BREAST HEALTH PROGRAMS WORLDWIDE. IT TAKES COLLABORATION AND STRONG PARTNERSHIPS TO MAKE A GLOBAL IMPACT. KOMEN STRIVES TO SERVE AS A "BRIDGE" - COLLABORATING WITH INTERNATIONAL NONPROFITS, CORPORATIONS, AND MINISTRIES OF HEALTH TO BRING TOGETHER PEOPLE AND ORGANIZATIONS TO DEVELOP PROGRAMS THAT ARE TAILORED TO THE SPECIFIC NEEDS OF THE COMMUNITY AND SENSITIVE TO CULTURAL DIFFERENCES. IN FY19, KOMEN'S GLOBAL PROGRAM AWARDED TEN GRANTS TO SUPPORT EDUCATION PROGRAMMING FOR PATIENTS AND FOR HEALTH PROFESSIONALS AND TO REDUCE BARRIERS TO BREAST CANCER CARE IN CHINA, COLOMBIA, MEXICO, PANAMA, AND ZAMBIA. |
| PUBLIC POLICY AND ADVOCACY | SUSAN G. KOMEN IS COMMITTED TO DOING EVERYTHING WE CAN TO SERVE MORE THAN 260,000 WOMEN AND MEN IN THE UNITED STATES WHO WILL BE DIAGNOSED WITH BREAST CANCER THIS YEAR, THE MORE THAN 150,000 WHO ARE CURRENTLY LIVING WITH INCURABLE BREAST CANCER, AND TO SAVE THE MORE THAN 42,000 WOMEN AND MEN WHO WILL LOSE THEIR LIVES IN 2019. THIS INCLUDES MOBILIZING THE VOICE OF EVERYONE IMPACTED BY THE DISEASE TO IMPROVE OUTCOMES AND SAVE LIVES THROUGH SOUND PUBLIC POLICY. ONLY THROUGH INFORMED GOVERNMENT ACTION CAN WE MAKE THE BROAD, SYSTEMIC AND LASTING CHANGE WE NEED TO HELP US ACHIEVE OUR BOLD GOAL OF REDUCING THE CURRENT NUMBER OF BREAST CANCER DEATHS BY 50% IN THE U.S. BY 2026. KOMEN WORKS TO ENSURE THAT THE FIGHT AGAINST BREAST CANCER IS A PRIORITY AMONG POLICYMAKERS IN WASHINGTON, D.C., AND EVERY STATE CAPITOL ACROSS THE COUNTRY. EVERY TWO YEARS, THROUGH A TRANSPARENT, BROAD-BASED AND INTENSIVE VETTING AND SELECTION PROCESS, KOMEN WORKS TO IDENTIFY THE POLICY ISSUES WITH THE GREATEST POTENTIAL MISSION IMPACT. THIS PROCESS INCLUDES COLLECTING FEEDBACK FROM KOMEN AFFILIATES FROM ACROSS THE COUNTRY; ADVISORY GROUPS INCLUDING ADVOCATES IN SCIENCE (AIS) AND KOMEN SCHOLARS; REPRESENTATIVES FROM THE METASTATIC BREAST CANCER COMMUNITY AND KOMEN'S AFRICAN AMERICAN HEALTH EQUITY INITIATIVE; AND OTHER STAKEHOLDERS WITH A VESTED INTEREST IN BREAST CANCER-RELATED ISSUES. THE SELECTED ISSUES ARE THE BASIS FOR KOMEN'S STATE AND FEDERAL ADVOCACY. KOMEN'S 2018-2019 ADVOCACY PRIORITIES INCLUDED: SUPPORTING EXPANDED FEDERAL FUNDING FOR BREAST CANCER RESEARCH AT THE NATIONAL INSTITUTES OF HEALTH (NIH) AND THE DEPARTMENT OF DEFENSE (DOD); SUPPORTING STATE AND FEDERAL FUNDING FOR THE CENTERS FOR DISEASE CONTROL AND PREVENTION'S (CDC) NATIONAL BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAM (NBCCEDP); ADVOCATING FOR STATE AND FEDERAL POLICIES TO IMPROVE INSURANCE COVERAGE OF BREAST CANCER TREATMENTS, INCLUDING THOSE THAT WOULD REQUIRE ORAL PARITY, PRECLUDE SPECIALTY TIERS AND PREVENT STEP THERAPY PROTOCOLS; ADVOCATING FOR STATE AND FEDERAL POLICIES TO REDUCE OR ELIMINATE OUT-OF-POCKET COSTS FOR MEDICALLY NECESSARY DIAGNOSTIC IMAGING; AND EVALUATING STATE AND FEDERAL POLICIES TO INCREASE PUBLIC ACCESS TO INFORMATION ABOUT AND PARTICIPATION IN CLINICAL TRIALS FOR ALL PATIENT POPULATIONS. IN ADDITION TO THE STATE AND FEDERAL WORK ON OUR 2018-2019 ADVOCACY PRIORITIES, KOMEN CONTINUED OUR EFFORTS TO ENSURE EVERY BREAST CANCER PATIENT AND SURVIVOR HAS ACCESS TO AFFORDABLE, QUALITY HEALTH INSURANCE AND CARE. KOMEN ALSO ENGAGED ON ISSUES RELATED TO BREAST DENSITY, COMPASSIONATE USE, GENETIC TESTING, LYMPHEDEMA, PALLIATIVE CARE AND SURVIVORSHIP. KOMEN DEVELOPED AND IMPLEMENTED ADVOCACY CAMPAIGNS TO ENCOURAGE LAWMAKERS AND AGENCY OFFICIALS TO SUPPORT AND IMPLEMENT PROGRAMS THAT WOULD ADVANCE OUR PRIORITY ISSUES AND ADDITIONAL POLICY AREAS TO ACHIEVE KOMEN'S BOLD GOAL. KOMEN CONTINUED TO RECRUIT AND ENGAGE ADVOCATES TO FURTHER STRENGTHEN ITS GRASSROOTS ADVOCACY NETWORK. SCREENING AND PATIENT NAVIGATION GETTING REGULAR SCREENING TESTS, ALONG WITH EFFECTIVE AND QUALITY TREATMENT IF DIAGNOSED, LOWERS THE RISK OF DYING FROM BREAST CANCER. SCREENING TESTS CAN FIND BREAST CANCER EARLY, WHEN CHANCES FOR SURVIVAL ARE HIGHEST. PATIENT NAVIGATION IS A PROCESS BY WHICH AN INDIVIDUAL - A PATIENT NAVIGATOR - GUIDES PATIENTS THROUGH AND AROUND BARRIERS IN THE COMPLEX CANCER CARE SYSTEM. EVIDENCE SHOWS NAVIGATION IMPROVES ADHERENCE TO SCREENING RECOMMENDATIONS, AND THUS IMPROVES OVERALL OUTCOMES. KOMEN SUPPORTS FREE AND LOW-COST SCREENING PROGRAMS IN UNDERSERVED COMMUNITIES THAT HELP NAVIGATE PEOPLE TO QUALITY CARE, AND/OR PROVIDE COVERAGE FOR SCREENING SERVICES TO PEOPLE WITHOUT HEALTH INSURANCE, OR THOSE WITH HIGH CO-PAYS AND DEDUCTIBLES THAT MAKE SCREENING TOO COSTLY. IN FY19, KOMEN AWARDED ONE SCREENING COMMUNITY GRANT TO BREAST CARE FOR WASHINGTON, TO DEVELOP A MOBILE MAMMOGRAPHY PROJECT TO INCREASE ACCESS TO QUALITY SCREENING AND NAVIGATE WOMEN INTO DIAGNOSIS AND TREATMENT. TREATMENT AND PATIENT NAVIGATION BARRIERS TO QUALITY CARE ARE OFTEN ASSOCIATED WITH POOR BREAST CANCER OUTCOMES AND RESULTANT CANCER DISPARITIES AMONG SPECIFIC POPULATION GROUPS. ACCORDING TO QUALITATIVE DATA COLLECTED FROM ACROSS KOMEN'S AFFILIATE NETWORK, THE MOST COMMON BARRIERS TO QUALITY CARE IN THE UNITED STATES INCLUDE: (1) AVAILABILITY OF LOCAL SERVICES; (2) BREAST CANCER EDUCATION; (3) CULTURAL/LANGUAGE; (4) FEAR; (5) FINANCIAL; (6) INSURANCE; (7) TRANSPORTATION. PATIENT NAVIGATION IS A PROCESS BY WHICH AN INDIVIDUAL - A PATIENT NAVIGATOR - GUIDES PATIENTS THROUGH AND AROUND BARRIERS IN THE COMPLEX CANCER CARE SYSTEM TO ENSURE TIMELY DIAGNOSIS AND TREATMENT. EVIDENCE SHOWS PATIENT NAVIGATION IMPROVES ADHERENCE TO TREATMENT RECOMMENDATIONS, RESULTING IN IMPROVED OUTCOMES. IN FY19, KOMEN FUNDED THREE NONPROFIT ORGANIZATIONS IN SUPPORT OF PROGRAMS TO REDUCE STRUCTURAL, PERSONAL, SOCIOCULTURAL, AND FINANCIAL BARRIERS TO CARE, AND PROVIDE PATIENT NAVIGATION SERVICES FOR UNDERSERVED COMMUNITIES IN THE WASHINGTON, D.C. METRO AREA, SPECIFICALLY WARDS 2, 5, 7, AND 8, AND ALEXANDRIA CITY, VA. KOMEN'S TREATMENT ASSISTANCE PROGRAM, ADMINISTERED BY CANCERCARE, AIMS TO HELP WOMEN AND MEN IN BREAST CANCER TREATMENT WHO ARE FACING FINANCIAL CHALLENGES STAY IN TREATMENT BY PROVIDING LIMITED FINANCIAL ASSISTANCE, EDUCATION, AND SUPPORT SERVICES. FINANCIAL ASSISTANCE IS GRANTED TO UNDERSERVED, UNDERINSURED OR UNINSURED WOMEN AND MEN ACROSS THE COUNTRY UNDERGOING BREAST CANCER TREATMENT WHO MEET PRE-DETERMINED ELIGIBILITY CRITERIA. THIS PROGRAM PROVIDES FINANCIAL ASSISTANCE FOR TREATMENT-RELATED COSTS, INCLUDING TRANSPORTATION TO AND FROM TREATMENT, CHILD/ELDER CARE, HOME CARE, ORAL PAIN/ANTI-NAUSEA MEDICATIONS, ORAL CHEMOTHERAPY/HORMONE THERAPY, LYMPHEDEMA CARE/SUPPLIES, PALLIATIVE CARE, AND DURABLE MEDICAL EQUIPMENT. WE SERVED MORE THAN 3500 PEOPLE THROUGH THIS PROGRAM IN FY19. |
| EXECUTIVE COMMITTEE | FORM 990, PART VI, LINE 1A THE ORGANIZATION'S BYLAWS PROVIDE FOR AN EXECUTIVE COMMITTEE COMPRISED OF A MINIMUM OF FIVE MEMBERS INCLUDING THE BOARD CHAIR, THE PRESIDENT AND CHIEF EXECUTIVE OFFICER, AND ADDITIONAL BOARD MEMBERS, AS RECOMMENDED BY THE GOVERNANCE COMMITTEE AND APPOINTED BY THE BOARD OF DIRECTORS. MEMBERS OF THE EXECUTIVE COMMITTEE MUST EITHER BE DIRECTORS OF THE ORGANIZATION OR THE PRESIDENT AND CHIEF EXECUTIVE OFFICER. THE BYLAWS PROVIDE THE EXECUTIVE COMMITTEE WITH THE AUTHORITY TO: (A) APPOINT MEMBERS TO NON-STANDING COMMITTEES OF THE ORGANIZATION, AND NAME CHAIRS OF SUCH COMMITTEES; (B) AUTHORIZE UNBUDGETED DISBURSEMENTS BY THE ORGANIZATION IN ACCORDANCE WITH THE SPECIFIC EXPENDITURE AUTHORITY PRESCRIBED BY THE BOARD OF DIRECTORS; (C) EMPLOY AGENTS; AND (D) CARRY INTO EXECUTION SUCH OTHER MEASURES AS IT DETERMINES WILL PROMOTE THE PURPOSE OF THE ORGANIZATION. THE COMMITTEE ALSO MAY EXERCISE, WHEN THE BOARD IS NOT IN SESSION, ALL OF THE AUTHORITY OF THE BOARD IN THE MANAGEMENT OF THE BUSINESS AND AFFAIRS OF THE ORGANIZATION WITH CERTAIN EXCEPTIONS SUCH AS REPEALING ANY BOARD RESOLUTIONS, AMENDING THE ORGANIZATION'S ARTICLES OR BYLAWS, OR MERGING OR DISSOLVING THE ORGANIZATION. THIS DELEGATION DOES NOT RELIEVE THE BOARD OF ANY OF ITS RESPONSIBILITIES IMPOSED BY LAW, AND THE COMMITTEE ENDEAVORS TO LIMIT ITS EXERCISE OF AUTHORITY TO TIME SENSITIVE ISSUES. |
| DESCRIBE THE PROCESS USED BY MANAGEMENT AND/OR GOVERNING BODY TO | REVIEW 990 FORM 990, PART VI, QUESTION 11B MANAGEMENT PREPARES THE MATERIALS FOR THE FORM 990, WITH THE ASSISTANCE OF AND REVIEW BY EXTERNAL ACCOUNTANTS. SENIOR LEVEL MANAGEMENT REVIEW AND COMMENT ON THE FINAL DRAFT OF THE FORM 990 FOR SUBSEQUENT PRESENTATION TO THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS. THE AUDIT COMMITTEE REVIEWS, MAKES RECOMMENDATIONS, AND APPROVES THE FORM 990 FOR PRESENTATION TO THE BOARD OF DIRECTORS. THEREAFTER, THE BOARD OF DIRECTORS REVIEWS AND APPROVES THE FORM 990 PRIOR TO FILING. |
| DESCRIPTION OF PROCESS TO MONITOR TRANSACTIONS FOR CONFLICTS OF INTEREST | FORM 990, PART VI, QUESTION 12C Komen's Conflict of Interest Policy requires every board member, officer, committee member, advisory board member, and employee to avoid conflicts of Interest. It also requires these persons to report any actual and/or potential conflicts of interest as soon as possible. Reports are reviewed by the General Counsel's office and/or Internal Audit, and appropriate action is taken pursuant to the Conflict of Interest Policy. Further, Komen produces an annual survey requiring all board members, officers, committee members, advisory board members, and employees to review the Conflict of Interest Policy and disclose any additional actual/potential conflicts of interest. These annual disclosures are reviewed in the same manner. The Audit Committee of the Board of Directors receives, and reviews all reported actual and potential conflicts of interest and the related action to address them. |
| OFFICES & POSITIONS FOR WHICH PROCESS WAS USED, & YEAR PROCESS WAS BEGUN | FORM 990, PART VI, QUESTION 15A & 15B THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS ASSISTS THE BOARD IN OVERSEEING COMPENSATION POLICIES AND BEST PRACTICES. RESPONSIBILITIES INCLUDE OVERSIGHT OF THE COMPENSATION OF THE CHIEF EXECUTIVE OFFICER; THE RANGE OF COMPENSATION LEVELS FOR THE ORGANIZATION'S OTHER OFFICERS, DISQUALIFIED PERSONS, AND OTHER KEY EMPLOYEES; GRANTING THE CHIEF EXECUTIVE OFFICER WITH THE AUTHORITY TO DETERMINE COMPENSATION LEVELS WITHIN AN APPROVED RANGE; AND ANY INCENTIVE/BONUS COMPENSATION PROGRAMS, IF APPROVED. THE CURRENT POLICY WAS ADOPTED IN 2010. A FORMAL COMPENSATION POLICY GOVERNS PAY PRACTICES. PERIODICALLY, ALL POSITIONS IN THE ORGANIZATION ARE REVIEWED AGAINST EXTERNAL MARKET DATA BY ENGAGING INDEPENDENT EXPERTS OR ACQUIRING UPDATED MARKET DATA TO CONDUCT THE BENCHMARKING PROCESS. COMPENSATION IS THEN BASED UPON COMPARABLE MARKET RATES OF PAY WITH CONSIDERATION FOR INTERNAL EQUITY AND THE FINANCIAL POSITION OF THE ORGANIZATION. BENCHMARKING WAS CONDUCTED FOR THE CHIEF EXECUTIVE OFFICER AND ALL EXECUTIVE TEAM MEMBERS' COMPENSATION TO EXTERNAL MARKET DATA IN 2019, TO ENSURE MARKET ALIGNMENT. KOMEN PROVIDES SALARY INCREASES, PROMOTIONS AND OTHER FORMS OF COMPENSATION WITHOUT REGARD TO RACE, COLOR, RELIGION, GENDER, NATIONAL ORIGIN, DISABILITY, VETERAN STATUS OR SEXUAL ORIENTATION. |
| AVAIL OF GOV DOCS, CONFLICT OF INTEREST POLICY, & FIN STMTS TO GEN PUBLIC | FORM 990, PART VI, QUESTION 19 KOMEN'S FINANCIAL STATEMENTS AND THE FORM 990 ARE PUBLICLY AVAILABLE ON OUR WEBSITE. THE CERTIFICATE OF FORMATION IS AVAILABLE FROM THE TEXAS SECRETARY OF STATE AND OTHER GOVERNING DOCUMENTS ARE MADE AVAILABLE AS REQUIRED BY STATE LAW. FORM 1023 AND THE CONFLICT OF INTEREST POLICY ARE NOT PUBLISHED ONLINE BUT ARE AVAILABLE TO THE PUBLIC UPON REQUEST. |
| ADDITIONAL DETAIL ON EVENT PRODUCTION EXPENSES INCLUDED ON OTHER EXP | FORM 990, PART IX, LINE 24 KOMEN PAYS 50% OF THE COST OF ALL T-SHIRTS FOR THE 111 SUSAN G. KOMEN RACE FOR THE CURE AND MORE THAN PINK WALK EVENTS CONDUCTED BY THE KOMEN AFFILIATES DURING THE FISCAL YEAR. ACCOUNTS RECEIVABLE FORM 990, PART X, LINE 4 The beginning of year amount for accounts receivable was determined by adding the amount of accounts receivable with pledges and grants receivable, net (line 3A). |
| OTHER CHANGES IN NET ASSETS OR FUND BALANCES | FORM 990, PART XI, LINE 9 RESCINDED GRANTS $1,681,546 UTAH FIELD OFFICE ADJUSTMENT $717 ----------------- TOTAL $1,682,263 ========== |
| Software ID: | |
| Software Version: |